bevantolol has been researched along with Chorea in 1 studies
bevantolol: structure given in first source
bevantolol : A propanolamine that is 3-aminopropane-1,2-diol in which the hydrogen of the primary hydroxy group is substituted by 3-methylphenyl and one of the hydrogens attached to the nitrogen is substituted by 2-(3,4-dimethoxyphenyl)ethyl. A beta1 adrenoceptor antagonist, it has been shown to be as effective as other beta-blockers for the treatment of angina pectoris and hypertension.
Chorea: Involuntary, forcible, rapid, jerky movements that may be subtle or become confluent, markedly altering normal patterns of movement. Hypotonia and pendular reflexes are often associated. Conditions which feature recurrent or persistent episodes of chorea as a primary manifestation of disease are referred to as CHOREATIC DISORDERS. Chorea is also a frequent manifestation of BASAL GANGLIA DISEASES.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Gamez, J | 2 |
Calopa, M | 2 |
Muñoz, E | 2 |
Ferré, A | 2 |
Huertas, O | 2 |
McAllister, K | 2 |
Reig, N | 2 |
Scart-Grès, C | 2 |
Insa, R | 2 |
Kulisevsky, J | 2 |
1 trial available for bevantolol and Chorea
Article | Year |
---|---|
A proof-of-concept study with SOM3355 (bevantolol hydrochloride) for reducing chorea in Huntington's disease.
Topics: Chorea; Double-Blind Method; Humans; Huntington Disease; Tetrabenazine; Treatment Outcome; Vesicular | 2023 |
A proof-of-concept study with SOM3355 (bevantolol hydrochloride) for reducing chorea in Huntington's disease.
Topics: Chorea; Double-Blind Method; Humans; Huntington Disease; Tetrabenazine; Treatment Outcome; Vesicular | 2023 |
A proof-of-concept study with SOM3355 (bevantolol hydrochloride) for reducing chorea in Huntington's disease.
Topics: Chorea; Double-Blind Method; Humans; Huntington Disease; Tetrabenazine; Treatment Outcome; Vesicular | 2023 |
A proof-of-concept study with SOM3355 (bevantolol hydrochloride) for reducing chorea in Huntington's disease.
Topics: Chorea; Double-Blind Method; Humans; Huntington Disease; Tetrabenazine; Treatment Outcome; Vesicular | 2023 |